<DOC>
	<DOCNO>NCT02878798</DOCNO>
	<brief_summary>The TopCSPN trial double blind randomize placebo control study oral topirmate potential disease alter therapy cryptogenic sensory peripheral neuropathy ( CSPN ) . Patients CSPN also metabolic syndrome ( define ATPIII criterion ) alternative cause neuropathy potentially eligible . The co primary outcome measure change Norfolk Quality Life - Diabetic Neuropathy ( NQOL-DN ) Scale intraepidermal nerve fiber density ( IEFND ) distal thigh . The treatment phase last 24 month .</brief_summary>
	<brief_title>Topiramate Cryptogenic Sensory Peripheral Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Age 1875 Diagnosis confirm cryptogenic symptomatic distal symmetric peripheral polyneuropathy base Toronto consensus criterion confirm neuropathy . Metabolic syndrome base ATPIII criterion . No history prior therapy topiramate . If female childbearing potential , willing use acceptable method birth control duration study 3 month follow completion study drug therapy . Acceptable method birth control include oral barrier method . Negative serum pregnancy test screen negative urine pregnancy test baseline visit . Any identified alternative cause peripheral neuropathy . All potential participant screen neuropathy lab include assessment diabetes ( Hemoglobin A1c , oral glucose tolerance test ) , vitamin B12 level , serum protein electrophoresis { England:2009cq } . Family history nondiabetic neuropathy firstdegree relative . Severe longstanding neuropathy : Utah Early Neuropathy Score &gt; 15 history foot ulceration amputation . Current plan therapeutic anticoagulation include coumadin oral factor X thrombin inhibitor therapy . Use oral prednisone . Use carbonic anhydrase inhibitor ( acetazolamide ) due risk nephrolithiasis . Screening laboratory value normal limit follow : AST/ALT ≥1.5 time upper limit normal , creatinine ≥2.0 mg/dl . Severe edema , dermatologic low extremity condition would increase risk skin biopsy . A serious medical condition expect dramatically shorten life span prevent participation . Any clinically significant condition illness , , opinion investigator , would pose risk participant might confound study . History alcohol drug abuse within one year study enrollment . History malignancy within five year prior study enrollment , except adequately treat basal cell squamous cell skin cancer situ cervical cancer . An inability understand cooperate procedure study . Pregnant , intend become pregnant , breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>